Hepatitis B virus (HBV) is a double-stranded DNA virus that results in human infection with acute and chronic disease phases in the liver. The acute phase of HBV infection is typically mild, often asymptomatic and self-resolves in up to 80% of cases. In both acute and chronic phases though, patients can infect others via bodily fluids. While very common in Africa and the western Pacific region, HBV incidence has been falling in the US and Europe as firstly the routine screening of donated blood, then vaccination programs and finally direct-acting antivirals reduced transmission, prevented infection and treated the disease, respectively. But two sets of patients remain stubborn outliers – those chronically infected with HBV and those that seem refractory to vaccination.
Stock Watch: The Stubborn Hurdle Of Chronic Hepatitis B
GSK Emerges As A Contender As Others Struggle
Most of the money raised by biotech companies to address chronic hepatitis B has resulted in failed programs. But wait, a glimmer of light from yonder pharma breaks.
More from Stock Watch
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
Two pharmaceutical companies reporting bumper sales in the hot areas of diabetes and obesity may have helped a thaw in sector sentiment.
More from Business
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.